Litcius/Paper detail

Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH

Thiago de Amorim Carvalho

2023Nature Medicine13 citationsDOI

Topics & Concepts

SteatohepatitisMedicineType 2 diabetesCohortClinical trialAgonistTranslational medicineInternal medicineDiabetes mellitusFatty liverType 2 Diabetes MellitusGastroenterologyEndocrinologyReceptorDiseasePathologyLiver Disease Diagnosis and TreatmentHepatitis C virus researchPeroxisome Proliferator-Activated Receptors
Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH | Litcius